SOST and bone disorder: The identification of genes involved in skeletal diseases can result in novel treatments for osteoporosis, as was the case for denosumab, an anti-RANKL monoclonal antibody [146,147] and romosozumab, an antibody against the Wnt-inhibitor sclerostin, SOST [148].